Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18811279 | 0.92 | KMT2A (0.70) | KMT2AEPHX2CASP3FABP5 | |
| SCHEMBL20759696 | 0.90 | KMT2A (0.78) | KMT2AEPHX2CASP3 | |
| SCHEMBL17089903 | 0.90 | KMT2A (0.62) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL5058821 | 0.89 | KMT2A (0.69) | KMT2AEPHX2CASP3FABP5 | |
| SCHEMBL12620066 | 0.89 | KMT2A (0.65) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL26032361 | 0.88 | KMT2A (0.58) | KMT2AEPHX2CASP3FABP5 | |
| SCHEMBL12665707 | 0.88 | KMT2A (0.67) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL26172640 | 0.87 | KMT2A (0.60) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL12391727 | 0.86 | KMT2A (0.57) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29397906 | 0.86 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| EP-4313051-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | Virginia Commonwealth University (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022212471-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2022-10-06 | — | — | WO | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20110263540-A1 | SMALL-MOLECULE INHIBITORS OF PROTEIN SYNTHESIS INACTIVATING TOXINS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2011-10-27 | — | — | US | disclosed |
| EP-1572669-A2 | 2,5-DIKETOPIPERAZINES FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004048345-A2 | 2,5-DIKETOPIPERAZINES FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263540-A1 | SMALL-MOLECULE INHIBITORS OF PROTEIN SYNTHESIS INACTIVATING TOXINS | MRPS27, MRPS22, MRPS23 | KMT2A 2997/4885EPHX2 4095/4885CASP3 4013/4885 |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | OPRM1, OPRK1, CCR5 | KMT2A 3025/4885EPHX2 578/4885CASP3 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.